Vertex Deal History & Licensing Activity
Vertex is a large pharma. Over the past three years, Vertex has been involved in 23 licensing and acquisition transactions, with a primary focus on Mab (6 deals). The company currently has 33 active clinical trials, primarily in Oncology.
Deals (12mo)
11
Active Trials
33
Top Modality
Mab
Focus Area
Oncology
Vertex Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Vertex in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| exagamglogene autotemcel | CRISPR Therapeutics | Gene Therapy | Approved | collaboration | Mar 2026 |
| SIRPα-001 | Revolution Medicines | mRNA | Preclinical | option | Jan 2026 |
| SIRPα-101 | BioNTech | Mab | Approved | option | Aug 2025 |
Vertex Pipeline Focus
Therapeutic areas and modalities where Vertex is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Vertex Strategic Signals
Key indicators of Vertex's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
- Undisclosed—
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Vertex Clinical Pipeline
Vertex has 33 active clinical trials across 4 development phases.
1
Unknown
9
Phase 1
6
Phase 2
17
Phase 3
See How Your Asset Matches Vertex's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
About Vertex Licensing & Deal Activity
Vertex is a large pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 23 deals over the past three years, Vertex ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Vertex include Oncology (22 deals and trials), Neurology (3 deals and trials), Metabolic (3 deals and trials), and Hematology (2 deals and trials). In terms of modality, Vertex has shown particular interest in mab, gene therapy, mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Vertex and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Vertex's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.